Overview


According to FutureWise analysis, the market for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is expected to grow at a CAGR of 9.70% over the forecast period of 2023-2031.

Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), or Skin and Soft Tissue Infections (SSTIs), encompass bacterial infections that impact the skin along with its related soft tissues, including loose connective tissue and mucous membranes. It is classified as complicated ABSSSIs and uncomplicated ABSSSIs. Complicated ABSSSI requires more extensive treatment and has distinct regulatory requirements, whereas the uncomplicated covers simple issues like boils, cellulitis, and abscesses. Complicated ABSSSI encompasses deeper tissues, surgical interventions, or underlying conditions complicating treatment response. Some sites, like the Rectal area, are also considered difficult due to their higher risks of specific pathogens. Common pathogens that cause this are staphylococcus aureus and streptococcus pyogenes.

The treatment interventions are decided based on the symptoms and locations, and the antibiotics are chosen. Broad-spectrum antibiotics are commonly used, which is causing antibiotic resistance issues. This is particularly notable in MRSA (Methicillin-Resistant Staphylococcus Aureus) species, frequently involved in ABSSSIs, leading to poorer outcomes and limited treatment options. Using tissue culture for microbiological evaluation has proven beneficial in guiding treatment decisions for less severe infections.

FutureWise Market Research has published a report that provides an insightful analysis of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization

  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Allergan plc
  • Merck & Co., Inc.
  • Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)
  • Fresenius SECo. KGaA
  • Sandoz Inc. (a subsidiary of Novartis)
  • Glenmark Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Cumberland Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:

  • In January 2022, Paladin Labs Inc., a subsidiary of Endo International PLC, introduced Xydalba (dalbavancin for injection) in Canada. This 30-minute intravenous (IV) therapy treats acute bacterial skin and skin structure infections (ABSSSI). It offers the flexibility of being administered as either a single- or two-dose regimen.

 
On the driver side, increased incidence of bacterial skin infections caused by factors like compromised immune systems and drug-resistant bacteria drives the market. There is a rise in the geriatric population, and this aging population pool is most prone to chronic diseases like ABSSSI, which is demanding market growth for its treatment. Technological advancements in diagnostic interventions, imaging techniques, and treatment modalities allow accurate and effective diagnosis and management for ABSSSI, contributing to the market’s revenue growth. Funds raised by the government for ongoing research and development is creating more opportunities for the invention of new antibiotics and alternative treatment options, including biological and innovative drug delivery system, which is fuelling the market. Expansion of healthcare expenditure and a stable healthcare industry allow more accessibility to individuals in healthcare facilities and services, thus propelling the market. Government initiatives to spread awareness through the campaigns also bolstered market growth.

However, along with the drivers, certain restraints affect market growth. High costs in developing and approving new drugs and interventions in the developing region are a significant barrier to the market. Stringent regulatory policies and approval processes can delay the entry of a new drug into the market and hamper market growth. Increased risk of side effects of the drugs and the treatment may deter the individual from continuing the process, which depletes the market growth.

By Active Ingredients

  • Delafloxacin
  • Vancomycin
  • Ceftaroline fosamil
  • Oritavancin
  • Tedizolid
  • Daptomycin
  • Tigecycline
  • Linezolid
  • Others

By Route of Administration

  • Oral
  • Parenteral
  •  opical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for the largest shareholder in this market in the forecast period due to the increased product approvals by the regulatory authorities, increased prevalence of the ABSSSI, a sizeable geriatric patient pool prone to these chronic diseases like ABSSSI, expanded healthcare infrastructure along with the increased healthcare expenditure is driving the market. In addition, government initiatives and funds they raised for awareness and research and development, respectively, propelling the market in this region.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market By Active Ingredients, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Variables, Trends and Scope

    •   1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Active Ingredients Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Delafloxacin
        2. Vancomycin
        3. Ceftaroline fosamil
        4. Oritavancin
        5. Tedizolid
        6. Daptomycin
        7. Tigecycline
        8. Linezolid
        9. Others

  • 8.   Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Parenteral
        3. Topical

  • 9.   Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.   North America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Paratek Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Melinta Therapeutics, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Allergan plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Merck & Co., Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Fresenius SECo. KGaA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sandoz Inc. (a subsidiary of Novartis)
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Glenmark Pharmaceuticals Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Cadila Healthcare Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Cumberland Pharmaceuticals Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Teva Pharmaceutical Industries Ltd.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11